02:11
Unknown
Sun Pharmaceutical Industries’ subsidiary has been granted a final approval from USFDA for its Abbreviated New Drug Applications (ANDA) for generic version of Prandin, Repaglinide tablets. Sun Pharma’s subsidiary, being the first-to-file an ANDA for generic Prandin with a Para IV certification, is eligible for a 180-day marketing exclusivity in the US.
Posted in: Indian Market Tips
0 comments:
Post a Comment